What is GHK-Cu?
A copper complex of a three-amino-acid peptide, glycyl-L-histidyl-L-lysine (GHK).
US legal status
Open question
Whether any 503A pharmacy may compound injectable GHK-Cu today is not settled: we found no basis for it. What the FDA's Pharmacy Compounding Advisory Committee will recommend for non-injectable GHK-Cu is also open; the FDA plans to consult it before the end of February 2027.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's adverse event database (FAERS, read November 16, 2026) holds 2 reports that name GHK-Cu, both serious and from the US, and both list it as a product taken alongside, not the suspect; the reports are not checked and do not show cause. In June 2025, another drug was the suspect, and the report lists anaphylactic shock, loss of consciousness and low blood pressure, with a hospital stay; in May 2026, a GLOW blend appears with other drugs, and the terms include malignant lymphoid neoplasm and "product dispensed by unauthorised provider".12
What the FDA has said
- The FDA says injectable GHK-Cu may pose "risk for immunogenicity due to the potential for aggregation and peptide-related impurities", and that there are "limited data in humans to inform safety-related considerations."3
- Under MoCRA, the responsible person must report a serious adverse event from a cosmetic to the FDA within 15 business days.9
No data
Product quality
- We found no published potency or contamination tests of GHK-Cu vials sold for injection.
Compounded GHK-Cu is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
- 1.FDA: Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 2.FDA: Bulk drug substances used in compounding under section 503A (content current as of 05/14/2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 3.FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (04/22/2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 4.FDA: Bulk drug substances nominated for use in compounding under section 503B (updated Mar 21, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 5.Federal Register, FR Doc. 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 6.HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Appendix A)Tier 1: regulator or registerhhs.govread Nov 16, 2026↩
- 7.FDA: Is it a cosmetic, a drug, or both? (or is it soap?) (09/11/2024)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 8.FDA: FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulated (11/18/2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 9.FDA: Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (10/29/2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 10.openFDA Drugs@FDA search (GHK, prezatide: no matches)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 11.openFDA NDC directory, generic name GHK* (8 bulk ingredient listings)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026
- 12.openFDA FAERS reports naming GHK-Cu (2 reports; data last updated Nov 13, 2026)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 13.Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 14.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 15.Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8(4):252-9Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 16.Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with GHK copper. Wound Repair Regen 1994;2(4):259-69Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 17.Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation: first-in-man pilot study. J Cosmet Laser Ther 2018;20(6):369-79Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 18.Patel MN et al. Scalp scrub and copper tripeptide serum regimen in seborrheic dermatitis. Cureus 2024;16(9):e70108Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 19.The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 20.Mayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026;54(1):223-9Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 21.PubMed searches for GHK-Cu and copper-peptide terms (totals, animals, humans, trials, by period)Tier 2: peer-reviewed or trial registryeutils.ncbi.nlm.nih.govread Nov 16, 2026↩
- 22.ClinicalTrials.gov search for GHK-Cu (4 studies)Tier 2: peer-reviewed or trial registryclinicaltrials.govread Nov 16, 2026↩
- 23.NCT07437586: Topical GHK-Cu gel for acute skin wound healing (phase 2, recruiting)Tier 2: peer-reviewed or trial registryclinicaltrials.govread Nov 16, 2026↩
- 24.WADA Prohibited List 2026 (S0 non-approved substances)Tier 1: regulator or registerwada-ama.orgread Nov 16, 2026↩
- 25.DEA: Controlled substances, alphabetical order (Nov 12, 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 26.FDA: Warning letters index, searches "GHK", "GHK-Cu", "copper peptide" (0 results) and "peptide" (25 letters dated 2025-2026, full text read)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 27.Federal Register API searches: "GHK-Cu", "copper peptide", "Pharmacy Compounding Advisory Committee", and 503A peptide compounding documents since Oct 30, 2026Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.